Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 14/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13169478 | 1.00 | PLK4 (0.70) | PLK4MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13169396 | 0.86 | PLK4 (0.61) | PLK4MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13169412 | 0.86 | CDK5 (0.67) | PLK4MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13169447 | 0.82 | PLK4 (0.62) | PLK4PIK3CAPIK3CBPIK3CG | |
| SCHEMBL7670538 | 0.82 | IKBKB (0.51) | PLK4MEN1NPC1RAB9AKMT2A | |
| SCHEMBL15466415 | 0.81 | PLK4 (0.47) | PLK4MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13169413 | 0.80 | PLK4 (0.79) | PLK4 | |
| SCHEMBL13169463 | 0.80 | TGM2 (0.56) | PLK4MEN1NPC1RAB9AKMT2A | |
| SCHEMBL3693031 | 0.80 | TGM2 (0.56) | PLK4MEN1NPC1RAB9AKMT2A | |
| SCHEMBL3693261 | 0.80 | MEN1 (0.47) | PLK4MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114900-B1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2018-10-10 | — | — | EP | disclosed |
| US-9040549-B2 | Thiopyrimidine-based compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040549-B2 | Thiopyrimidine-based compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8846704-B2 | Thiopyrimidine-based compounds and uses thereof | YM Biosciences Austraila Pty Ltd (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846704-B2 | Thiopyrimidine-based compounds and uses thereof | YM Biosciences Austraila Pty Ltd (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846704-B2 | Thiopyrimidine-based compounds and uses thereof | YM Biosciences Austraila Pty Ltd (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-20 | — | — | US | disclosed |
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-13 | — | — | US | disclosed |
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2014-02-13 | — | — | US | disclosed |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD | 2010-09-23 | — | — | US | disclosed |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD | 2010-09-23 | — | — | US | disclosed |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045848-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | PLK4 533/4885MEN1 2801/4885NPC1 4321/4885 |
| US-20100239631-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | PLK4 533/4885MEN1 2801/4885NPC1 4321/4885 |
| US-20140051703-A1 | THIOPYRIMIDINE-BASED COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | PLK4 533/4885MEN1 2801/4885NPC1 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.